AORT Stock: Price, Earnings History and SEC Filings
Artivion, Inc. (AORT) last traded at $22.58, down 3.67% on the latest session and down 1.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.13 against an analyst estimate of $0.13, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AORT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $0.13 | $0.13 | +0.00% |
| Mar 2026 | May 7, 2026 | $0.08 | $0.06 | +33.33% |
| Dec 2025 | Feb 12, 2026 | $0.17 | $0.14 | +21.43% |
| Sep 2025 | Nov 6, 2025 | $0.16 | $0.14 | +14.29% |
AORT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How AORT reacts to earnings
Across its last 8 earnings releases, AORT moved 11.9% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | After close | +2.07% |
| 2026-05-07 | After close | -28.26% |
| 2026-02-12 | After close | -9.96% |
| 2025-11-06 | After close | -5.54% |
| 2025-08-07 | After close | +25.23% |
| 2025-05-05 | After close | +15.36% |
| 2025-02-24 | After close | -8.22% |
| 2024-11-07 | After close | -0.93% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AORT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $441M | $10M | $839000 | 2.2% | $0.21 |
| 2024 | $389M | -$13M | $11M | -3.4% | $-0.32 |
| 2023 | $354M | -$31M | $9M | -8.7% | $-0.75 |
| 2022 | $314M | -$19M | -$16M | -6.1% | $-0.48 |
| 2021 | $299M | -$15M | -$16M | -5.0% | $-0.38 |
| 2020 | $253M | -$17M | $5M | -6.6% | $-0.44 |
| 2019 | $276M | $2M | $8M | 0.6% | $0.05 |
| 2018 | $263M | -$3M | $4M | -1.1% | $-0.08 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AORT
- 10-Q · Aug 7, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- 8-K · May 18, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 8-K · May 15, 2026Shareholder vote
- 10-Q · May 8, 2026
- 8-K · May 7, 2026Material agreement, Results of operations, Financial statements and exhibits
- DEF 14A · Apr 1, 2026
- 10-K · Feb 18, 2026
- 8-K · Feb 12, 2026Results of operations, Financial statements and exhibits
- 10-Q · Nov 7, 2025
Insider filing activity
AORT insiders filed 6 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AORT news
- Artivion to Participate in Upcoming Investor ConferencesOct 28, 2026 · finance.yahoo.com
- OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue EstimatesOct 27, 2026 · finance.yahoo.com
- Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial ResultsOct 22, 2026 · finance.yahoo.com
- Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the restOct 22, 2026 · finance.yahoo.com
- Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’Oct 20, 2026 · finance.yahoo.com
- Artivion (AORT) Stock May Be 13% Undervalued On Cash FlowOct 20, 2026 · finance.yahoo.com
About Artivion, Inc.
Artivion, Inc. (AORT) is a US-listed public company on NYSE. The SEC classifies its business as Surgical & Medical Instruments & Apparatus. It is incorporated in DE. Its fiscal year ends in December.